Corporate ActionMay 1, 2026, 05:27 PM
Regentis Biomaterials Files F-1 for 3.33M Share Public Offering
AI Summary
Regentis Biomaterials Ltd. filed an F-1 registration statement for a public offering of 3,333,334 ordinary shares at an assumed price of $3.00 per share, with an over-allotment option for 500,000 additional shares. The company provided updates on its GelrinC pivotal trial, having recruited 47 of 80 initial patients and expecting to complete recruitment by Q3 2026, aiming for PMA submission by the end of 2027. Additionally, Regentis announced key management changes, including a new CEO, CFO, and CMO, and a new collaboration with Humanitas Research Hospital in Europe.
Key Highlights
- Regentis Biomaterials filed an F-1 registration for a public offering of 3,333,334 ordinary shares.
- The assumed public offering price is $3.00 per share, with ThinkEquity as the underwriter.
- The underwriter has a 45-day option to purchase up to 500,000 additional ordinary shares.
- 47 out of 80 required patients have been recruited for the GelrinC pivotal trial, with 43 completing two-year follow-up.
- Patient recruitment for the pivotal trial is expected to complete in Q3 2026, with PMA submission by end of 2027.
- Dr. Ehud Geller was appointed CEO, Mr. Ori Gon as CFO, and Dr. Galit Reske as Chief Medical Officer.
- The company announced a collaboration with Humanitas Research Hospital in Milan, Italy.